Literature DB >> 20812007

Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients.

A Nakashima1, J J Carrero, A R Qureshi, T Hirai, N Takasugi, T Ueno, Y Taniguchi, B Lindholm, N Yorioka.   

Abstract

UNLABELLED: A high circulating osteoprotegerin (OPG) level may be a risk factor for vascular calcification and mortality in hemodialysis patients. OPG and pulse wave velocity (PWV) were measured at baseline in 151 normoalbuminemic, long-term (>3 years) Japanese hemodialysis patients who were prospectively followed for 6 years. In long-term normoalbuminemic Japanese hemodialysis patients, OPG levels were strongly linked with both arterial stiffness and worse outcome.
INTRODUCTION: A high circulating OPG level is reported to be a risk factor for vascular calcification and mortality in Western chronic kidney disease (CKD) patients but it is not known if this is true for Japanese CKD patients, where a different risk profile may operate.
METHODS: OPG and PWV were measured at baseline in 151 normoalbuminemic, long-term (>3 years) Japanese hemodialysis patients (median age 62 years) who were prospectively followed for 6 years.
RESULTS: OPG levels were associated in multivariate analysis with age, dialysis vintage, history of cardiovascular disease (CVD) and parathyroid hormone levels. C-reactive protein levels did not correlate with OPG. Patients with clinical history of CVD had significantly higher OPG levels and OPG levels were positively correlated to PWV, an index of arterial stiffness. These associations were independent of age, sex, dialysis vintage, and diabetes. During the follow-up period, 40 deaths, including 25 cardiovascular deaths, were recorded. In crude analysis, each unit of increase in OPG was associated with increased all-cause (hazard ratios 1.14, 95% confidence interval 1.08-1.20) and CVD mortality (1.14 [1.07-1.21]), which persisted after adjustment for age, sex, dialysis vintage, diabetes, and baseline CVD (1.12 [1.05-1.19] and 1.11 [1.02-1.19], all-cause and CVD mortality, respectively).
CONCLUSIONS: In long-term normoalbuminemic Japanese hemodialysis patients, with low prevalence of inflammation, OPG levels were strongly linked with both arterial stiffness and worse outcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20812007     DOI: 10.1007/s00198-010-1377-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  28 in total

1.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

2.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.

Authors:  P A Price; H H June; J R Buckley; M K Williamson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-10       Impact factor: 8.311

Review 5.  Vascular calcifications: pathogenesis, management, and impact on clinical outcomes.

Authors:  Jorge B Cannata-Andía; Minerva Rodríguez-García; Natalia Carrillo-López; Manuel Naves-Díaz; Bernardino Díaz-López
Journal:  J Am Soc Nephrol       Date:  2006-12       Impact factor: 10.121

6.  Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease.

Authors:  Keisuke Matsubara; Peter Stenvinkel; Abdul Rashid Qureshi; Juan Jesús Carrero; Jonas Axelsson; Olof Heimbürger; Peter Bárány; Anders Alvestrand; Bengt Lindholm; Mohamed E Suliman
Journal:  J Nephrol       Date:  2009 Nov-Dec       Impact factor: 3.902

7.  Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  David A Goodkin; Jennifer L Bragg-Gresham; Karl G Koenig; Robert A Wolfe; Takashi Akiba; Vittorio E Andreucci; Akira Saito; Hugh C Rayner; Kiyoshi Kurokawa; Friedrich K Port; Philip J Held; Eric W Young
Journal:  J Am Soc Nephrol       Date:  2003-12       Impact factor: 10.121

8.  Assessment of myeloperoxidase and oxidative alpha1-antitrypsin in patients on hemodialysis.

Authors:  Hirokazu Honda; Masashi Ueda; Shiho Kojima; Shinichi Mashiba; Yuki Hirai; Nozomu Hosaka; Hiroki Suzuki; Masanori Mukai; Makoto Watanabe; Keiko Takahashi; Kanji Shishido; Tadao Akizawa
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-07       Impact factor: 8.237

9.  Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease.

Authors:  Maria Mesquita; Anne Demulder; Nasroolla Damry; Christian Mélot; Eric Wittersheim; Dominique Willems; Max Dratwa; Pierre Bergmann
Journal:  Clin Chem Lab Med       Date:  2009       Impact factor: 3.694

10.  Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.

Authors:  H Min; S Morony; I Sarosi; C R Dunstan; C Capparelli; S Scully; G Van; S Kaufman; P J Kostenuik; D L Lacey; W J Boyle; W S Simonet
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

View more
  12 in total

Review 1.  Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication.

Authors:  Sinee Disthabanchong
Journal:  World J Nephrol       Date:  2012-04-06

2.  Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease.

Authors:  Julia J Scialla; Mary B Leonard; Raymond R Townsend; Lawrence Appel; Myles Wolf; Matt J Budoff; Jing Chen; Eva Lustigova; Crystal A Gadegbeku; Melanie Glenn; Asaf Hanish; Dominic Raj; Sylvia E Rosas; Stephen L Seliger; Matthew R Weir; Rulan S Parekh
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-22       Impact factor: 8.237

3.  Receptor activator of nuclear factor κB ligand/osteoprotegerin axis and vascular calcifications in patients with chronic kidney disease.

Authors:  Michalis Spartalis; Aikaterini Papagianni
Journal:  World J Nephrol       Date:  2016-01-06

4.  Elevated levels of serum sclerostin are linked to adverse cardiovascular outcomes in peritoneal dialysis patients.

Authors:  Li Gong; Dongxia Zheng; Jiangzi Yuan; Liou Cao; Zhaohui Ni; Wei Fang
Journal:  Int Urol Nephrol       Date:  2018-01-22       Impact factor: 2.370

5.  Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease.

Authors:  M M Nascimento; S Y Hayashi; M C Riella; B Lindholm
Journal:  Braz J Med Biol Res       Date:  2014-08-22       Impact factor: 2.590

6.  Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients.

Authors:  Panagiotis Pateinakis; Aikaterini Papagianni; Stella Douma; Georgios Efstratiadis; Dimitrios Memmos
Journal:  BMC Nephrol       Date:  2013-06-12       Impact factor: 2.388

7.  Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients.

Authors:  Jung Eun Lee; Hyung Jong Kim; Sung Jin Moon; Ji Sun Nam; Jwa-Kyung Kim; Seung Kyu Kim; Gi Young Yun; Sung Kyu Ha; Hyeong Cheon Park
Journal:  Korean J Intern Med       Date:  2013-10-29       Impact factor: 2.884

8.  Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function.

Authors:  Sílvia Collado; Elisabeth Coll; Carlos Nicolau; Manel Azqueta; Mercedes Pons; Josep M Cruzado; Bernat de la Torre; Ramón Deulofeu; Sergi Mojal; Julio Pascual; Aleix Cases
Journal:  BMC Nephrol       Date:  2017-09-07       Impact factor: 2.388

9.  Osteoprotegerin and Cardiovascular Events in High-Risk Populations: Meta-Analysis of 19 Prospective Studies Involving 27 450 Participants.

Authors:  Lena Tschiderer; Gerhard Klingenschmid; Rajini Nagrani; Johann Willeit; Jari A Laukkanen; Georg Schett; Stefan Kiechl; Peter Willeit
Journal:  J Am Heart Assoc       Date:  2018-08-21       Impact factor: 5.501

10.  Association of serum osteoprotegerin levels with carotid-femoral pulse wave velocity in hypertensive patients.

Authors:  Ji-Hung Wang; Chung-Jen Lee; Mei-Ling Chen; Chiu-Fen Yang; Yu-Chih Chen; Bang-Gee Hsu
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-03-19       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.